<?xml version="1.0" encoding="UTF-8"?>
<p id="p0180">Darunavir (DRV) is a second-generation protease inhibitor against HIV-1. Scientists in China declared on 4 February 2020 that DRV prevented 
 <italic>in vitro</italic> SARS-CoV-2 infection. Cell research demonstrated that DRV reported to inhibit viral replication at a concentration of 300 μM 
 <italic>in vitro</italic>, and its inhibition efficacy was 280 times that of the untreated group [
 <xref rid="bb0555" ref-type="bibr">111</xref>]. In patients with COVID-19 pneumonia, DRV is used in trial number 
 <ext-link ext-link-type="ClinicalTrials.gov" xlink:href="NCT04252274" id="ir0350" xmlns:xlink="http://www.w3.org/1999/xlink">NCT04252274</ext-link> in combination with cobicistat [
 <xref rid="bb0560" ref-type="bibr">112</xref>]. Such a combination is currently approved by the FDA in treating AIDS. DRV is a HIV protease inhibitor, and cobicistat is a supplement to enhance DRV's pharmacodynamics and pharmacokinetics by inhibiting cytochrome P450 (CYP3A) [
 <xref rid="bb0565" ref-type="bibr">113</xref>,
 <xref rid="bb0570" ref-type="bibr">114</xref>].
</p>
